keyword
MENU ▼
Read by QxMD icon Read
search

'Hodgkin lymphoma'

keyword
https://www.readbyqxmd.com/read/29236346/therapy-related-acute-myeloid-leukaemia-and-myelodysplastic-syndrome-in-victoria-australia-2003-2014
#1
Doen Ming Ong, Helen Farrugia, Andrew Wei
BACKGROUND: The burden of therapy-related acute myeloid leukaemia (tAML) / therapy-related myelodysplastic syndrome (tMDS) in Australia has not been characterized. METHODS: We analysed adults aged ≥20 years at diagnosis of acute myeloid leukaemia (AML) / myelodysplastic syndrome (MDS) reported to the Victorian Cancer Registry (VCR) between 2003-2014. RESULTS: 73/3,120 (2.3%) AML cases were classified tAML. tAML patients were younger than non-tAML patients at diagnosis (median age 66 vs...
December 13, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/29234945/clinical-significance-and-functional-validation-of-inorganic-pyrophosphatase-in-diffuse-large-b-cell-lymphoma-in-humans
#2
Limei Li, Aruna, Dehong Luo, Arong Jin
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma, displays marked heterogeneity. Although it is usually curable, 30-40% of patients die within 1-2 years due to refractory treatment or cancer relapse. In different types of cancer in humans, inorganic pyrophosphatase (PPA1) is deregulated, thereby contributing to tumorigenesis by supplying the tumor with an enormous energy source. However, the role of PPA1 in DLBCL is still unclear. Here, we analized PPA1 in 65 patients with DLBCL and 20 patients with reactive hyperplasia of the lymph nodes (control)...
December 12, 2017: Cytotechnology
https://www.readbyqxmd.com/read/29233743/a-phase-ii-trial-of-rituximab-combined-with-pegfilgrastim-in-patients-with-indolent-b-cell-non-hodgkin-lymphoma
#3
Pallawi Torka, Priyank Patel, Wei Tan, Gregory Wilding, Seema A Bhat, Myron S Czuczman, Kelvin P Lee, George Deeb, Vishala Neppalli, Cory Mavis, Paul Wallace, Francisco J Hernandez-Ilizaliturri
BACKGROUND: To explore the role of augmenting neutrophil function in B-cell lymphoma, we conducted a phase II study evaluating the safety and clinical efficacy of pegfilgrastim and rituximab in low-grade CD20+ B-cell non-Hodgkin lymphoma (B-NHL). PATIENTS AND METHODS: Twenty patients with indolent B-NHL were treated with rituximab (375 mg/m2) every other week for 4 doses, followed by every 2 months for 4 additional doses. Pegfilgrastim was administered subcutaneously 3 days before each dose of rituximab...
November 6, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29233742/how-to-approach-a-hodgkin-lymphoma-patient-with-relapse-after-autologous-sct-allogeneic-sct
#4
REVIEW
Matthew Mei, Robert Chen
Hodgkin lymphoma (HL) is a highly curable B-cell lymphoma, and ∼90% of patients who present with early-stage (stage I-II) disease and 70% of patients who present with late-stage disease will be cured with standard frontline treatment. For patients with relapsed or refractory (r/r) disease after initial therapy, the standard of care is salvage chemotherapy, followed by autologous transplantation (autoSCT). Although this approach will cure a significant proportion of patients, upto 50% of patients will experience disease progression after autoSCT, and this population has historically had a very poor prognosis...
December 9, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29233497/early-and-late-survival-of-on-pump-cardiac-surgery-patients-formerly-affected-by-lymphoma
#5
Giuseppe Gatti, Oscar Maraldo, Bernardo Benussi, Rossana Bussani, Gianluca Castaldi, Gianfranco Sinagra, Aniello Pappalardo
BACKGROUND: Survival after cardiac surgery of patients formerly affected by lymphoma has not been well defined. METHODS: Forty-five consecutive patients having prior Hodgkin's (HL patients, n=26) or non-Hodgkin's lymphoma (non-HL patients, n=19) underwent on-pump cardiac surgery at the authors' institution (2001-2016). Ischaemic, valvular, and ischaemic plus valvular heart disease were present in 14, 13, and 18 patients, respectively. Concomitant aortic disease was treated in three cases...
November 28, 2017: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/29232438/refractory-or-relapsed-aggressive-b-cell-lymphoma-failing-r-chop-an-analysis-of-patients-treated-on-the-ricover-60-trial
#6
B Glass, A J Dohm, L H Truemper, M Pfreundschuh, A Bleckmann, G G Wulf, A Rosenwald, M Ziepert, N Schmitz
Background: The prognosis of elderly patients with aggressive B-non-Hodgkin's lymphoma after first lymphoma-related treatment failure (TF-L) is not well described. Methods: We analysed patient characteristics including the presence of MYC rearrangements and MYC-expression immunohistochemistry (IHC) at diagnosis and modalities of salvage therapy and their impact on the prognosis of patients between 61 and 80 years who had been treated on the RICOVER-60 trial. Results: TF-L occurred in 301 of the 1222 (24...
December 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29231971/enzooty-of-non-hodgkin-s-malignant-lymphoma-of-papio-hamadryas-in-sukhumi-monkey-colony-clinical-and-morphological-signs-of-pre-lymphoma
#7
Lelita A Yakovleva, Boris A Lapin, Aslan A Agumava
Inoculation of hamadryas baboons with blood of leukemia ill people-induced malignant non-Hodgkin's lymphoma in experimental animals for a very considerable latency period. At close contact of inoculated baboons with healthy non-inoculated animals, the lymphoma spread between them. The epidemiological analysis, postmortem examination, histological analysis, tissue culturing, and PCR were used for the diagnostics of lymphoma and pre-lymphoma, purification, identification of STLV-1, and HVP viruses. Characteristic clinical and morphological signs designated by us as pre-lymphoma often precede the lymphoma development...
December 12, 2017: Journal of Medical Primatology
https://www.readbyqxmd.com/read/29230339/nodular-lymphocyte-predominant-hodgkin-lymphoma-of-the-ileum
#8
Aruna Rangan, Sarah W Grahn, Andrew L Feldman
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma derived from germinal center B lymphocytes that typically presents with localized lymph node involvement and can mimic a variety of both reactive and other neoplastic conditions. Extranodal involvement is uncommon in NLPHL and typically occurs in the context of previously documented or synchronous nodal disease. Involvement of the gastrointestinal tract is exceedingly rare. Here, we present the first case to our knowledge of NLPHL involving the ileum that was discovered incidentally on routine screening colonoscopy in an asymptomatic patient...
2017: Case Reports in Pathology
https://www.readbyqxmd.com/read/29230244/tumor-lysis-syndrome-in-patients-with-hematological-malignancies
#9
REVIEW
Yohannes Belay, Ketsela Yirdaw, Bamlaku Enawgaw
Tumor lysis syndrome is a metabolic complication that may follow the initiation of cancer therapy. It commonly occurs in hematological malignant patients particularly non-Hodgkin's lymphoma and acute leukemia due to chemotherapy or spontaneously. It is characterized by a biochemical abnormality such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia and its clinical outcome is directly related to these biochemical abnormalities. Prevention and treatment of tumor lysis syndrome depend on immediate recognition of patients at risk...
2017: Journal of Oncology
https://www.readbyqxmd.com/read/29230194/acute-flaccid-paralysis-by-enterovirus-d68-infection-first-italian-description-in-adult-patient-and-role-of-electrophysiology
#10
Marco Ceccanti, Emilia Sbardella, Federica Letteri, Manuela De Michele, Anne Falcou, Federica Romanzi, Emanuela Onesti, Maurizio Inghilleri
A Peruvian woman was admitted to the Emergency Department, due to an acute flaccid paralysis (AFP) of the upper limbs that progressively involved also lower limbs and respiratory muscles. She previously suffered from non-Hodgkin's lymphoma and had to undergo hematopoietic stem cell transplantation. A magnetic resonance imaging showed a T2 hyperintensity in the anterior and central region of the cervical segment with an elective involvement of gray matter. This finding, combined with other clinical, laboratory, and electrophysiological data, led to a diagnosis of AFP...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/29229594/interim-results-of-brentuximab-vedotin-in-combination-with-nivolumab-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma
#11
Alex F Herrera, Alison J Moskowitz, Nancy L Bartlett, Julie M Vose, Radhakrishnan Ramchandren, Tatyana A Feldman, Ann S LaCasce, Stephen M Ansell, Craig H Moskowitz, Keenan Fenton, Carol Anne Ogden, David Taft, Qu Zhang, Kazunobu Kato, Mary Campbell, Ranjana H Advani
In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administered in combination were evaluated as initial salvage therapy in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL) (ClinicalTrials.gov #NCT02572167). Patients received up to 4 cycles of combination treatment, with BV administered on Day 1 and Nivo on Day 8 of the first cycle. For Cycles 2-4, BV and Nivo were both administered on Day 1. Following study treatment, responses were evaluated by investigators per the 2014 Lugano classification, and patients could proceed to autologous stem cell transplantation (ASCT)...
December 11, 2017: Blood
https://www.readbyqxmd.com/read/29229324/comparison-of-36%C3%A2-gy-20%C3%A2-gy-or-no-radiation-therapy-after-6-cycles-of-ebvp-chemotherapy-and-complete-remission-in-early-stage-hodgkin-lymphoma-without-risk-factors-results-of-the-eort-gela-h9-f-intergroup-randomized-trial
#12
José Thomas, Christophe Fermé, Evert M Noordijk, Franck Morschhauser, Théodore Girinsky, Isabelle Gaillard, Pieternella J Lugtenburg, Marc André, Marnix L M Lybeert, Aspasia Stamatoullas, Max Beijert, Philippe Hélias, Houchingue Eghbali, Jean Gabarre, Richard W M van der Maazen, Jérôme Jaubert, Krimo Bouabdallah, Olivier Boulat, Judith M Roesink, Bernard Christian, Francisca Ong, Dominique Bordessoule, Gérard Tertian, Hugo Gonzalez, Andrej Vranovsky, Philippe Quittet, Umberto Tirelli, Daphne de Jong, Josée Audouin, Berthe M P Aleman, Michel Henry-Amar
PURPOSE: While patients with early-stage Hodgkin lymphoma (HL) have an excellent outcome with combined treatment, the radiation therapy (RT) dose and treatment with chemotherapy alone remain questionable. This noninferiority trial evaluates the feasibility of reducing the dose or omitting RT after chemotherapy. METHODS AND MATERIALS: Patients with untreated supradiaphragmatic HL without risk factors (age ≥ 50 years, 4 to 5 nodal areas involved, mediastinum-thoracic ratio ≥ 0...
October 27, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29228840/investigational-pd-1-inhibitors-in-hl-and-nhl-and-biomarkers-for-predictors-of-response-and-outcome
#13
Andres Chang, Danielle Schlafer, Christopher R Flowers, Pamela B Allen
Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. Areas covered: We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response. Expert opinion: We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents...
December 12, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29228756/interim-pet-ct-may-predict-pfs-and-os-in-t-all-lbl-adult-patients
#14
Liang Wang, Jing-Hua Wang, Xi-Wen Bi, Xiao-Qin Chen, Yue Lu, Zhong-Jun Xia
T lymphoblastic leukemia/lymphoma (T-ALL/LBL) is highly aggressive. Although intensive chemotherapies such as ALL-type regimens are commonly used, about half adult patients eventually relapse and die of T-ALL/LBL. Overwhelming evidences have confirmed that interim PET can predict survival outcomes and guide subsequent treatments in Hodgkin lymphoma. However, whether interim PET-CT can predict survival outcomes or not in T-ALL/LBL patients remains unclear. 47 adult patients of T-ALL/LBL were retrospectively reviewed...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29226345/palisading-neutrophilic-and-granulomatous-dermatitis-as-a-presentation-of-hodgkin-lymphoma-a-case-and-review
#15
Jacqueline Deen, Leith Banney, Joanna Perry-Keene
Palisaded neutrophilic and granulomatous dermatitis (PNGD) is a histopathological diagnosis, characterized by a pattern of granulomatosis, which may be associated with leukocytoclastic vasculitis. PNGD most commonly occurs in association with systemic inflammatory disorders, typically autoimmune conditions, such as rheumatoid arthritis and systemic lupus erythromatosus. There are very rare reports of PNGD in patients with lymphoma. We report the case of a 53-year-old female with an erythematous, papular eruption occurring in association with Hodgkin lymphoma...
December 11, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/29225854/tyrosine-kinase-inhibitor-and-rituximab-chop-treatment-for-concurrent-chronic-myeloid-leukemia-and-non-hodgkin-lymphoma-a-case-report
#16
Yuki Takeyasu, Atsushi Satake, Yoshiko Azuma, Yukie Tsubokura, Hideaki Yoshimura, Masaaki Hotta, Takahisa Nakanishi, Shinya Fujita, Aya Nakaya, Tomoki Ito, Shosaku Nomura
Non-Hodgkin lymphoma can occur concurrently with chronic phase-chronic myeloid leukemia (CML) at initial diagnosis. Combination treatment with second-generation tyrosine kinase inhibitors and rituximab-CHOP for patients newly diagnosed with CML and non-Hodgkin lymphoma is effective for both diseases. However, we found that this treatment combination may induce severe myelosuppression.
December 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/29225710/novel-developments-in-the-pathogenesis-and-diagnosis-of-extranodal-marginal-zone-lymphoma
#17
REVIEW
Max I Schreuder, Michiel van den Brand, Konnie M Hebeda, Patricia J T A Groenen, J Han van Krieken, Blanca Scheijen
Extranodal marginal zone lymphoma (EMZL), mostly represented by mucosa-associated lymphoid tissue (MALT) type, also referred to as MALT lymphoma, is a clinically heterogeneous entity within the group of low-grade B cell lymphomas that arises in a wide range of different extranodal sites, including the stomach, lung, ocular adnexa, and skin. It represents the third most common non-Hodgkin lymphoma in the Western world, and the median age of occurrence is around 60 years. One characteristic aspect in a subset of EMZL detectable in about 25% of the cases is the presence of specific chromosomal translocations involving the genes MALT1 and BCL10, which lead to activation of the NF-κB signaling pathway...
December 2017: Journal of Hematopathology
https://www.readbyqxmd.com/read/29225679/relapsed-hodgkin-s-lymphoma-in-pregnancy-a-case-review
#18
Rhiannon George-Carey, Maryam Parisaei, Wiece Koniman, Micaela Pluckinski, Jonathan Lambert
Hodgkin's lymphoma is rarely diagnosed in pregnancy, occurring in 1:6000 deliveries. However, improvements in survival and the use of less gonadotoxic treatments have increased the number of Hodgkin's lymphoma survivors becoming pregnant. Both de novo and relapsed Hodgkin's lymphoma in pregnancy pose difficult decisions for both clinicians and patients. This review discusses important diagnostic and treatment considerations of relapsed Hodgkin's lymphoma in pregnancy. We discuss a difficult case which illustrates these particular dilemmas and suggests the evidence behind different modalities of investigation and management...
December 2017: Obstetric Medicine
https://www.readbyqxmd.com/read/29224505/progress-in-the-treatment-of-hodgkin-s-lymphoma
#19
Dan L Longo, Vincent T DeVita
No abstract text is available yet for this article.
December 10, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29224502/brentuximab-vedotin-with-chemotherapy-for-stage-iii-or-iv-hodgkin-s-lymphoma
#20
Joseph M Connors, Wojciech Jurczak, David J Straus, Stephen M Ansell, Won S Kim, Andrea Gallamini, Anas Younes, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Maranda, Yasuhiro Oki, Tatyana Feldman, Piotr Smolewski, Kerry J Savage, Nancy L Bartlett, Jan Walewski, Robert Chen, Radhakrishnan Ramchandren, Pier L Zinzani, David Cunningham, Andras Rosta, Neil C Josephson, Eric Song, Jessica Sachs, Rachael Liu, Hina A Jolin, Dirk Huebner, John Radford
Background Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. Methods We conducted an open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) and 670 were assigned to receive doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The primary end point was modified progression-free survival (the time to progression, death, or noncomplete response and use of subsequent anticancer therapy) as adjudicated by an independent review committee...
December 10, 2017: New England Journal of Medicine
keyword
keyword
27364
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"